SHERI SPIRT

PSYCHIATRY

16 East 96th Street Unit 1A

New York, N.Y. 10128

(212) 595 6901

SSDR18@aol.com

www.sherispirtmd.com

**LATUDA**

* Atypical antipsychotic agent
* High affinity for D2, 5-HT2a and 5HT7 receptors
* Antidepressant effect mediated by 5HT7 antagonism
* Demonstrated antidepressant efficacy in Bipolar disorder both as a monotherapy and as an adjunctive therapy with lithium or valproate

Side effects:

Nausea, somnolence, dizziness, akathisia, abdominal discomfort, dry mouth, and parkinsonism. Minimal weight changes. No meaningful changes in measurements of lipids, glycemic indices, prolactin levels, or EKG changes.

Studies show significant improvement in depressive symptoms compare to placebo and improvement in depressive symptoms in those patients that present with mixed features. Manic and hypomanic symptoms also improve. There is also improvement in anxiety.

Pharmacology

Half life: 18 hours

Metabolized by CYP 3A4

Peak plasma time 1-3 hours

Take with food.